These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34950677)

  • 21. New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
    Nurjadi D; Kocer K; Chanthalangsy Q; Klein S; Heeg K; Boutin S
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0201121. PubMed ID: 34871093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant
    He Y; Wang Y; Ma X; Zhao L; Guan J; Zhao J; Yu W; Li Y; Ni W; Gao Z
    Infect Drug Resist; 2022; 15():7177-7187. PubMed ID: 36514799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure
    Kocer K; Boudour-Halil D; Chanthalangsy Q; Sähr A; Heeg K; Boutin S; Nurjadi D
    Antimicrob Agents Chemother; 2023 May; 67(5):e0011823. PubMed ID: 37022155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal.
    Daoud L; Allam M; Collyns T; Ghazawi A; Saleem A; Al-Marzooq F
    Eur J Clin Microbiol Infect Dis; 2023 Nov; 42(11):1395-1400. PubMed ID: 37828413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
    Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
    Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
    Jabbour JF; Sharara SL; Kanj SS
    Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
    Lee YR; Yeo S
    Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
    Yamano Y
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.
    Giacobbe DR; Ciacco E; Girmenia C; Pea F; Rossolini GM; Sotgiu G; Tascini C; Tumbarello M; Viale P; Bassetti M;
    Infect Drug Resist; 2020; 13():4697-4711. PubMed ID: 33402840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
    Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
    Falcone M; Tiseo G; Nicastro M; Leonildi A; Vecchione A; Casella C; Forfori F; Malacarne P; Guarracino F; Barnini S; Menichetti F
    Clin Infect Dis; 2021 Jun; 72(11):2021-2024. PubMed ID: 32941593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
    Malik S; Kaminski M; Landman D; Quale J
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868330
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains.
    Padovani M; Bertelli A; Corbellini S; Piccinelli G; Gurrieri F; De Francesco MA
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
    AlMatar M; Albarri O; Makky EA; Var I; Köksal F
    Mini Rev Med Chem; 2020; 20(18):1908-1916. PubMed ID: 32811410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.